FS).The secondary endpoint is overall survival and no cross-over will be allowed between the study arms.(4) A Phase III CELESTIAL trial of Cometriq in patients with advanced hepatocellular carcinoma The trial is expected to enroll 760 patients with advanced HCC who have received prior sorafenib,Xavier Rhodes Jersey, and the primary endpoint is OS.The secondary endpoints include objective response rate and progression-free survival .| 歡迎光臨 汽車旅館論壇 (https://bbs.104mm.com/) | Powered by Discuz! X3.2 |